• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

    1/7/21 8:00:00 AM ET
    $TRIL
    $PHAT
    $RCKT
    $PASG
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRIL alert in real time by email

    MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.

    Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.

    Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.

    Max Nowicki, M.D., joined the Frazier Life Sciences team in 2019 and focuses on identifying new public and private investment opportunities. He has been involved in numerous Frazier investments, including Rocket Pharmaceuticals (NASDAQ: RCKT) and Trillium Therapeutics (NASDAQ: TRIL).

    “We are thrilled to announce the promotions of Aditya, Anna, and Max,” said James Topper, Managing Partner at Frazier. “They are extremely valuable members of our team, and are instrumental in helping us create new companies, as well as invest in new public and private companies.”

    About Frazier Healthcare Partners

    Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.

    For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

    Get the next $TRIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRIL
    $PHAT
    $RCKT
    $PASG

    CompanyDatePrice TargetRatingAnalyst
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/12/2025$28.00Strong Buy
    Raymond James
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/9/2025$16.00Equal Weight
    Barclays
    Rocket Pharmaceuticals Inc.
    $RCKT
    11/18/2025Neutral → Underweight
    Analyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    8/20/2025$10.00Neutral → Buy
    BofA Securities
    Rocket Pharmaceuticals Inc.
    $RCKT
    7/25/2025$4.00Buy → Neutral
    BofA Securities
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/30/2025$5.00Outperform → In-line
    Evercore ISI
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025Overweight → Neutral
    Analyst
    More analyst ratings

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

    FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference in Boston, MADate: Monday, March 2, 2026Company Presentation: 10:30 am ESTManagement to participate in one-on-one meetings throughout the conference Jefferies Biotech on the Beach Summit in Miami, FLDate: Tuesday, March 10, 2026 Management to participate in one-on-one meetings throughout the

    2/23/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference and Leerink Partners Global Healthcare Conference in Boston and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and management will host investor meetings at each conference. Participation details are as follows: TD Cowen 46th Annual Health Care Conference Date: March 2, 2026 Time: 11:10 AM ET Leerink Partners Global Healthcare Conference Date: Ma

    2/23/26 7:00:00 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Passage Bio to Participate in Upcoming Investor Conferences

    PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Thursday, February 26, 2026Presentation Time: 8:40 a.m. ETLocation: Virtual TD Cowen 46th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 4, 2026Presentation Time: 1:50 p.m. ETLocation:

    2/19/26 7:00:00 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Militello John sold $3,862 worth of shares (1,157 units at $3.34), decreasing direct ownership by 1% to 91,019 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    2/20/26 4:31:44 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Shah Gaurav sold $19,995 worth of shares (5,990 units at $3.34), decreasing direct ownership by 0.57% to 1,046,055 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    2/20/26 4:26:14 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Wilson Martin sold $4,593 worth of shares (1,376 units at $3.34), decreasing direct ownership by 0.20% to 682,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    2/20/26 4:09:54 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bjork Elisabeth bought $34,400 worth of shares (10,000 units at $3.44), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    1/6/26 4:05:11 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lynx1 Capital Management Lp bought $2,261 worth of shares (325 units at $6.96) and bought $221,474 worth of shares (31,683 units at $6.99) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    9/15/25 8:05:45 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bjork Elisabeth bought $34,100 worth of shares (10,000 units at $3.41), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    8/27/25 8:54:13 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on Phathom Pharmaceuticals with a new price target

    Raymond James initiated coverage of Phathom Pharmaceuticals with a rating of Strong Buy and set a new price target of $28.00

    12/12/25 8:54:28 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Phathom Pharmaceuticals with a new price target

    Barclays initiated coverage of Phathom Pharmaceuticals with a rating of Equal Weight and set a new price target of $16.00

    12/9/25 8:52:32 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    SEC Filings

    View All

    SEC Form 144 filed by Rocket Pharmaceuticals Inc.

    144 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    2/18/26 4:58:31 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Rocket Pharmaceuticals Inc.

    144 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    2/18/26 4:50:33 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

    SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    2/13/26 4:10:03 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Leadership Updates

    Live Leadership Updates

    View All

    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

    Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. "We welcome Sanjeev to Phathom's leadership team at this important stage of our growth," said Steve Basta, President

    10/6/25 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards to Ms. Cook under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Ms. Cook was granted a non-qualified stock option to purchase

    6/23/25 4:15:00 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Financials

    Live finance-specific insights

    View All

    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

    FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion o

    2/17/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarterFull-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) --  Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third q

    10/30/25 7:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

    Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A

    10/20/25 8:00:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Passage Bio Inc.

    SC 13G - Passage BIO, Inc. (0001787297) (Subject)

    11/14/24 12:03:11 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

    SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    11/8/24 10:52:38 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care